Trending
Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...
Pharma’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy
Many pharma companies have begun shifting their R&D portfolios to the development of new cancer drugs. A pharma company recently announced a bold new cancer drug R&D portfolio strategy where the company will focus on early-stage cancers over late-stage (advanced) cancers for new drug development. This shift in focus goes against the standard target development paradigm where companies ...